Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine vs 3+7 Chemotherapy in Older AML (AML21)
NCT02172872Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2014
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of decitabine in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02172872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172872.